Marinomed Biotech AG (VIE:MARI)
Austria flag Austria · Delayed Price · Currency is EUR
19.90
-0.05 (-0.25%)
Oct 3, 2025, 5:35 PM CET

Marinomed Biotech AG Cash Flow Statement

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202015 - 2019
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Net Income
9.12-15.42-6.37-6.4-5.89-6.01
Upgrade
Depreciation & Amortization
0.360.410.450.40.380.23
Upgrade
Other Amortization
---0.270.230.2
Upgrade
Loss (Gain) From Sale of Assets
----0.01-0
Upgrade
Asset Writedown & Restructuring Costs
0.650.65----
Upgrade
Other Operating Activities
-10.9311.952.210.991.230.23
Upgrade
Change in Accounts Receivable
---1.52-0.78-2.04
Upgrade
Change in Inventory
----0.53-0.1-0.83
Upgrade
Change in Accounts Payable
----1.450.851.34
Upgrade
Change in Other Net Operating Assets
---0.01-0.770
Upgrade
Operating Cash Flow
-0.8-2.4-3.7-5.2-4.87-6.88
Upgrade
Capital Expenditures
----0.23-0.92-3.96
Upgrade
Sale of Property, Plant & Equipment
---0.02--
Upgrade
Other Investing Activities
---0.1---
Upgrade
Investing Cash Flow
---0.1-0.21-0.92-3.96
Upgrade
Long-Term Debt Issued
---82.48
Upgrade
Long-Term Debt Repaid
----0.22-0.32-0.29
Upgrade
Net Debt Issued (Repaid)
---7.782.087.71
Upgrade
Issuance of Common Stock
----0.30.31
Upgrade
Other Financing Activities
1.41.6-1.7--0-0.01
Upgrade
Financing Cash Flow
1.41.6-1.77.782.388.01
Upgrade
Miscellaneous Cash Flow Adjustments
--0.1--00.03
Upgrade
Net Cash Flow
0.6-0.9-5.52.37-3.4-2.81
Upgrade
Free Cash Flow
-0.8-2.4-3.7-5.43-5.79-10.85
Upgrade
Free Cash Flow Margin
-8.20%-50.08%-39.37%-46.24%-49.75%-133.53%
Upgrade
Free Cash Flow Per Share
-0.45-1.35-2.44-3.62-3.92-7.37
Upgrade
Cash Interest Paid
---0.450.360.21
Upgrade
Levered Free Cash Flow
-1.24-1.1-3.37-5.17-5.56-9.54
Upgrade
Unlevered Free Cash Flow
-0.86-0.5-2.51-3.6-4.62-9.09
Upgrade
Change in Working Capital
----0.46-0.81-1.53
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.